Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
Cornea Research Foundation of America
Study ID
NCT03248037
Phase
PHASE3
Status
Completed

Conditions

  • Bullous Keratopathy
  • Fuchs' Endothelial Dystrophy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Netarsudil — DRUG
    netarsudil opthalmic solution 0.02%
  • Placebo — DRUG
    Placebo eye drops

Study Details

Cornea transplant recipients who are using topical corticosteroids long-term to prevent transplant rejection will be randomized to use netarsudil or placebo.

Key Dates

Start date
Sep 5, 2017
Status verified
Jan 2021
Primary completion
Jul 9, 2019
Completion
Jul 9, 2019

Study Design

Enrollment
120 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Netarsudil
    Netarsudil ophthalmic solution 0.02%, dosed topically once a day for 9 months
  • Placebo Comparator: Placebo
    Placebo eye drop, dosed topically once a day for 9 months

Primary Outcome Measure

Intraocular Pressure [ Time Frame: from date of randomization until the date of first documented intraocular pressure elevation exceeding defined threshold up to 9 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Price Vision GroupIndianapolisIndiana46260-

Find similar trials in Indianapolis, IN

By research site
Price Vision Group· Indianapolis, IN

Related Studies